Renato Bassan

Summary

Affiliation: Ospedali Riuniti
Country: Italy

Publications

  1. doi Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)
    Renato Bassan
    Unità Strutturale Complessa di Ematologia, Ospedali Riuniti, Bergamo, Italy
    Blood 113:4153-62. 2009
  2. ncbi Adult acute lymphoblastic leukaemia
    Renato Bassan
    Ospedali Riuniti, Bergamo, Italy
    Crit Rev Oncol Hematol 50:223-61. 2004
  3. doi Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00
    Renato Bassan
    U S C Ematologia, Ospedali Riuniti, Bergamo, Italy
    J Clin Oncol 28:3644-52. 2010
  4. doi Modern therapy of acute lymphoblastic leukemia
    Renato Bassan
    Ospedali Riuniti, Largo Barozzi 1, 24128 Bergamo, Italy
    J Clin Oncol 29:532-43. 2011
  5. ncbi Evolving strategies for the management of high-risk adult acute lymphoblastic leukemia
    Renato Bassan
    Division of Hematology, Ospedali Riuniti, Bergamo, Italy
    Haematologica 90:1299. 2005
  6. ncbi Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia
    Orietta Spinelli
    Hematology and Bone Marrow Transplantation Units of Ospedali Riuniti Bergamo, Bergamo, Italy
    Haematologica 92:612-8. 2007
  7. doi Results of a lymphoblastic leukemia-like chemotherapy program with risk-adapted mediastinal irradiation and stem cell transplantation for adult patients with lymphoblastic lymphoma
    Sergio Cortelazzo
    Division of Hematology, Ospedale Civile, Bolzano, Italy
    Ann Hematol 91:73-82. 2012
  8. doi A short low-dose imatinib trial allows rapid identification of responsive patients in hypereosinophilic syndromes
    Tamara Intermesoli
    Unità Strutturale Complessa di Ematologia, Ospedali Riuniti, Bergamo, Italy
    Br J Haematol 147:681-5. 2009
  9. ncbi The sensitivity of acute lymphoblastic leukemia cells carrying the t(12;21) translocation to campath-1H-mediated cell lysis
    Josee Golay
    Laboratory of Cellular and Gene Therapy G Lanzani, Division of Haematology, Ospedali Riuniti di Bergamo, Bergamo, Italy
    Haematologica 91:322-30. 2006
  10. ncbi Prolonged administration of all-trans retinoic acid in combination with intensive chemotherapy and G-CSF for adult acute myelogenous leukemia: single-centre pilot study in different risk groups
    Renato Bassan
    Division of Haematology, Cytogenetics Unit, Ospedali Riuniti, Bergamo, Italy
    Hematol J 3:193-200. 2002

Collaborators

Detail Information

Publications16

  1. doi Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)
    Renato Bassan
    Unità Strutturale Complessa di Ematologia, Ospedali Riuniti, Bergamo, Italy
    Blood 113:4153-62. 2009
    ..001) using a level of 10(-4) or higher to define persistent disease. MRD analysis during early postremission therapy improves risk definitions and bolsters risk-oriented strategies. ClinicalTrials.gov identifier: NCT00358072...
  2. ncbi Adult acute lymphoblastic leukaemia
    Renato Bassan
    Ospedali Riuniti, Bergamo, Italy
    Crit Rev Oncol Hematol 50:223-61. 2004
    ..Therapeutic progress may be obtainable through a careful integration of chemotherapy, stem cell transplantation, and the new targeted treatments with highly specific metabolic inhibitors and humanised monoclonal antibodies...
  3. doi Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00
    Renato Bassan
    U S C Ematologia, Ospedali Riuniti, Bergamo, Italy
    J Clin Oncol 28:3644-52. 2010
    ....
  4. doi Modern therapy of acute lymphoblastic leukemia
    Renato Bassan
    Ospedali Riuniti, Largo Barozzi 1, 24128 Bergamo, Italy
    J Clin Oncol 29:532-43. 2011
    ..These changes are improving long-term outcome, which in ongoing studies is expected close to 50% or greater...
  5. ncbi Evolving strategies for the management of high-risk adult acute lymphoblastic leukemia
    Renato Bassan
    Division of Hematology, Ospedali Riuniti, Bergamo, Italy
    Haematologica 90:1299. 2005
  6. ncbi Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia
    Orietta Spinelli
    Hematology and Bone Marrow Transplantation Units of Ospedali Riuniti Bergamo, Bergamo, Italy
    Haematologica 92:612-8. 2007
    ..The aim of this study was to correlate the kinetics of MRD clearance after allogeneic transplantation with the clinical outcome of adults with ALL...
  7. doi Results of a lymphoblastic leukemia-like chemotherapy program with risk-adapted mediastinal irradiation and stem cell transplantation for adult patients with lymphoblastic lymphoma
    Sergio Cortelazzo
    Division of Hematology, Ospedale Civile, Bolzano, Italy
    Ann Hematol 91:73-82. 2012
    ....
  8. doi A short low-dose imatinib trial allows rapid identification of responsive patients in hypereosinophilic syndromes
    Tamara Intermesoli
    Unità Strutturale Complessa di Ematologia, Ospedali Riuniti, Bergamo, Italy
    Br J Haematol 147:681-5. 2009
    ..Low-dose, short-course imatinib may represent a rational choice for identifying responsive cases, both within and outside the pre-defined FIP1L1 rearrangement subset...
  9. ncbi The sensitivity of acute lymphoblastic leukemia cells carrying the t(12;21) translocation to campath-1H-mediated cell lysis
    Josee Golay
    Laboratory of Cellular and Gene Therapy G Lanzani, Division of Haematology, Ospedali Riuniti di Bergamo, Bergamo, Italy
    Haematologica 91:322-30. 2006
    ..Campath-1H is used in conditioning regimens and more recently as an anti-leukemic therapy in acute lymphoblastic leukemias (ALL). We therefore investigated CD52 expression and campath-1H-mediated lysis of ALL cells in vitro...
  10. ncbi Prolonged administration of all-trans retinoic acid in combination with intensive chemotherapy and G-CSF for adult acute myelogenous leukemia: single-centre pilot study in different risk groups
    Renato Bassan
    Division of Haematology, Cytogenetics Unit, Ospedali Riuniti, Bergamo, Italy
    Hematol J 3:193-200. 2002
    ..An exploratory trial was conducted to evaluate toxicity and potential therapeutic role of all trans-retinoic acid (ATRA) given long-term together with chemotherapy and G-CSF to adult patients with acute myelogenous leukemia (AML)...
  11. ncbi Abnormally expanded pro-B hematogones associated with congenital cytomegalovirus infection
    Tamara Intermesoli
    USC Ematologia, Ospedali Riuniti, Bergamo, Italy
    Am J Hematol 82:934-6. 2007
    ....
  12. ncbi Immunophenotypic evaluation of circulating T-cell clones in hypereosinophilic syndromes with or without abnormal CD3 and CD4 lymphocytes
    Renato Bassan
    Division of Hematology, Ospedali Riuniti, Bergamo Italy
    Haematologica 89:238-9. 2004
  13. ncbi Phase I trial with escalating doses of idarubicin and multidrug resistance reversal by short-course cyclosporin A, sequential high-dose cytosine arabinoside, and granulocyte colony-stimulating factor for adult patients with refractory acute leukemia
    Renato Bassan
    Department of Hematology, Ospedali Riuniti, Largo Barozzi 1, 24100 Bergamo, Italy
    Haematologica 87:257-63. 2002
    ..The principal aim was to define the maximum tolerated dose (MTD) of IDR, which is reported to be a less MDR1-sensitive anthracycline. The short CsA infusion was patterned after the results of a previous in vitro study...
  14. ncbi Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients
    Ilaria Iacobucci
    Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Bologna, Italy
    Clin Cancer Res 12:3037-42. 2006
    ..CCgR is durable in the majority of patients but relapse occurs in a subset...
  15. ncbi Transplant-finalized salvage of adult acute lymphoblastic leukemia: results of a mitoxantrone- and methotrexate-based regimen in 36 patients
    Eros Di Bona
    Department of Haematology, Vicenza Hospital, Vicenza, Italy
    Leuk Lymphoma 46:879-84. 2005
    ..In spite of 12 HSCTs, there was no long-term survivor. 'ABC' salvage proved feasible and comparable to reported rescue chemotherapic regimens, but the achievement of cure in refractory/relapsing ALL remains an outstanding clinical task...
  16. ncbi Adult acute myeloid leukaemia
    Matthew Smith
    St Bartholomew s Hospital, London, UK
    Crit Rev Oncol Hematol 50:197-222. 2004
    ....